Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity
- PMID: 17367162
- DOI: 10.1021/mp060121r
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity
Abstract
Efflux pump (e.g., P-gp, MRP1, and BCRP) inhibition has been recognized as a strategy to overcome multi-drug resistance and improve drug bioavailability. Besides small-molecule inhibitors, surfactants such as Tween 80, Cremophor EL, several Pluronics, and Vitamin E TPGS (TPGS 1000) are known to modulate efflux pump activity. Competitive inhibition of substrate binding, alteration of membrane fluidity, and inhibition of efflux pump ATPase have been proposed as possible mechanisms. Focusing on TPGS 1000, the aim of our study was to unravel the inhibitory mechanism by comparing the results of inhibition experiments in a Caco-2 transport assay with data from electron spin resonance (ESR) and from ATPase activity studies. ESR results, on Caco-2 cells using 5-doxyl stearic acid (5-SA) as a spin probe, ruled out cell membrane fluidization as a major contributor; change of membrane fluidity was only observed at surfactant concentrations 100 times higher than those needed to achieve full efflux inhibition. Concurrently, TPGS 1000 inhibited substrate induced ATPase activity without inducing significant ATPase activity on its own. By investigating TPGS analogues that varied by their PEG chain length, and/or possessed a modified hydrophobic core, transport studies revealed that modulation of ATPase activity correlated with inhibitory potential for P-gp mediated efflux. Hence, these results indicate that ATPase inhibition is an essential factor in the inhibitory mechanism of TPGS 1000 on cellular efflux pumps.
Similar articles
-
Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.Int J Pharm. 2009 Mar 31;370(1-2):93-102. doi: 10.1016/j.ijpharm.2008.11.021. Epub 2008 Nov 30. Int J Pharm. 2009. PMID: 19100824
-
Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity.Mol Pharm. 2014 Jan 6;11(1):71-80. doi: 10.1021/mp4004223. Epub 2013 Nov 22. Mol Pharm. 2014. PMID: 24256068
-
Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access.Mol Pharm. 2010 Jun 7;7(3):642-51. doi: 10.1021/mp900191s. Mol Pharm. 2010. PMID: 20205474
-
[Recent advance in the mechanism study of polymeric inhibitors of P-glycoprotein].Yao Xue Xue Bao. 2010 Oct;45(10):1224-31. Yao Xue Xue Bao. 2010. PMID: 21348299 Review. Chinese.
-
Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future.Pharmaceutics. 2023 Feb 21;15(3):722. doi: 10.3390/pharmaceutics15030722. Pharmaceutics. 2023. PMID: 36986583 Free PMC article. Review.
Cited by
-
Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.Br J Pharmacol. 2015 Jul;172(14):3596-610. doi: 10.1111/bph.13149. Epub 2015 May 19. Br J Pharmacol. 2015. PMID: 25825339 Free PMC article.
-
Design, Fabrication and Evaluation of Stabilized Polymeric mixed micelles for Effective Management in Cancer Therapy.Pharm Res. 2022 Nov;39(11):2761-2780. doi: 10.1007/s11095-022-03395-8. Epub 2022 Sep 28. Pharm Res. 2022. PMID: 36171346
-
Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Nano Today. 2013 Jun 1;8(3):313-331. doi: 10.1016/j.nantod.2013.04.006. Nano Today. 2013. PMID: 23888183 Free PMC article.
-
Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery.AAPS PharmSciTech. 2015 Jun;16(3):610-22. doi: 10.1208/s12249-014-0244-2. Epub 2014 Nov 26. AAPS PharmSciTech. 2015. PMID: 25425389 Free PMC article.
-
Formulation, Characterization And Evaluation Of Curcumin- Loaded PLGA- TPGS Nanoparticles For Liver Cancer Treatment.Drug Des Devel Ther. 2019 Oct 16;13:3569-3578. doi: 10.2147/DDDT.S211748. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31802845 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous